Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer

NCT03325816 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer
Small Cell Lung Cancer Extensive Stage

Interventions

DRUG: Nivolumab
RADIATION: 177Lu-DOTA0-Tyr3-Octreotate

Sponsor

Georgetown University

Collaborators

[object Object]
[object Object]